Bio-X
Showing 101-108 of 108 Results
-
Zijie Sun
Professor of Urology, Emeritus
Current Research and Scholarly InterestsWe focus on understanding the molecular mechanism of transcription factors that govern the transformation of normal cells to a neoplastic state. We are especially interested in nuclear hormone action and its interactions with other signaling pathways in tumor development and progression.
-
John B. Sunwoo
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor, by courtesy, of Dermatology
Current Research and Scholarly InterestsMy laboratory is focused on two primary areas of research: (1) the immune response to head and neck cancer and to a tumorigenic population of cells within these malignancies called cancer stem cells; (2) the developmental programs of a special lymphocyte population involved in innate immunity called natural killer (NK) cells; and (3) intra-tumor and inter-tumor heterogeneity.
-
Trisha Suppes, MD, PhD
Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology-Adult)
Current Research and Scholarly InterestsLong-term treatment strategies for bipolar disorder, treatment for bipolar II disorder, use of treatment algorithms, and treatment of major depression.
-
Yuri Suzuki
Professor of Applied Physics and, by courtesy, of Materials Science and Engineering
Current Research and Scholarly InterestsHer interests are focused on novel ground states and functional properties in condensed matter systems synthesized via atomically precise thin film deposition techniques with a recent emphasis has been on highly correlated electronic systems:
• Emergent interfacial electronic & magnetic phenomena through complex oxide heteroepitaxy
• Low dimensional electron gas systems
• Spin current generation, propagation and control in complex oxide-based ferromagnets
• Multifunctional behavior in complex oxide thin films and heterostructures -
Katrin J Svensson
Assistant Professor of Pathology
Current Research and Scholarly InterestsMolecular metabolism
Protein biochemistry
Cell biology and function
Animal physiology -
James Swartz
James H. Clark Professor in the School of Engineering and Professor of Chemical Engineering and of Bioengineering
BioProfessor Swartz received his first lessons in resourcefulness and persistence growing up on a farm in South Dakota. After earning a BS in Chemical Engineering with Highest Honors from S. Dak. School of Mines and Technology, he began his professional career with Union Oil Co. of CA in Casper, Wyoming. Serving in the Drilling, Reservoir Engineering, and Production Departments provided an appreciation of the complexity and importance of large scale energy technologies. That experience also strengthened his belief that biological technologies offered the power and versatility to better address evolving societal needs. The MIT graduate programs in chemical engineering (MS) and biochemical engineering (Dsc) helped strengthen his biological training while broadening an appreciation for this emerging field. Following a 3 month exchange visit to the Soviet Union, he gained additional experience at Eli Lilly and participated in the development of the first recombinant DNA pharmaceutical to be approved, rDNA insulin. After two years, he moved to Genentech to help establish their drug production capability, developing the fermentation process for their first product, rDNA growth hormone.
After 17 years at Genentech in various line and project leadership positions, he joined the Stanford Chemical Engineering Department with a focus on an embryonic technology called cell-free protein synthesis (CFPS). Multiple technology breakthroughs from his lab motivated the founding of Sutro Biopharma which now has four promising anti-cancer drugs in clinical trials. A new company called Vaxcyte later spun out of Sutro to focus on complex human vaccines enabled by CFPS. Both companies are now publicly traded. Another company, GreenLight Biosciences, is focusing on inexpensive, large scale RNA production for use against agricultural pests. At Stanford, Professor Swartz is now focusing on expanding the basic capabilities of cell-free bioprocess while also developing technologies for targeted drug development, vaccines, circulating tumor cell assays, the carbon negative production of commodity biochemicals, and for economically attractive photosynthetic hydrogen production. -
Karl Sylvester
Professor of Surgery (Pediatric Surgery) at the Stanford University Medical Center
Current Research and Scholarly InterestsOne of the current primary interests of the lab is to investigate the mechanisms by which hepatocellular injury and recovery is influenced and controlled by hepatocyte metabolism.
A second focus of investigation is to identify molecular markers of human disease that provide diagnostic function, serve as targets for possible therapeutic manipulation, or provide insight into mechanisms of human disease. Specific diseases of interest include newborn sepsis and Necrotizing Enterocolitis (NEC). -
Daniel Sze, MD, PhD
Professor of Radiology (Interventional Radiology) at the Stanford University Medical Center
Current Research and Scholarly InterestsTransarterial administration of chemotherapeutics, radioactive microspheres, and biologics for the treatment of unresectable tumors; management of portal hypertension and complications of cirrhosis (TIPS); treatment of complications of organ transplantation; Venous and pulmonary arterial thrombolysis and reconstruction; Stent and Stent-graft treatment of peripheral vascular diseases, aneurysms, aortic dissections